News & Views
Key Roles to Support both Technology and Business Evolvement
Feb 26 2020
Biopharmaceutical company Phoremost has announced the appointments of Dr Catherine Beech as Non-Executive Director and Dr Benedict (Ben) Cross, who has joined as Senior Director (Technology), with responsibility for directing the evolution and development of the Company’s screening platform.
Catherine has over 25 years of biotech and pharmaceutical industry experience, including leading drug development programmes in hypertension, heart failure, Parkinson’s disease and HIV. She has also worked extensively to commercialise novel technologies in the life sciences and is a scientific founder and CEO of Exonate. Catherine has a degree in medicine from the University of Birmingham and in 2008 was awarded an OBE for services to technology and innovation.
Ben is a geneticist and biotechnologist with over ten years of professional research and management experience. He joins the company from Horizon Discovery, where he established and led the company’s functional genomic screening platform over a period of six years. The screening group now executes hundreds of screens per year, generating multi-million-pound revenue. Ben completed his PhD at the University of Manchester, with postdoctoral training at the University of Cambridge.
Dr Chris Torrance, CEO, PhoreMost, said: “We welcome both Ben and Catherine to the PhoreMost team at this exciting point in the Company’s development. We very much look forward to working with Ben to maximise the potential of the SITESEEKER platform and to the addition of Catherine’s valuable experience and guidance on the Board of Directors.”
Dr Catherine Beech, OBE, Non-Executive Director, PhoreMost, said: “I am absolutely delighted to join the Board of PhoreMost. I believe the Company is poised for success, and that 2020 will be a tremendous year on many fronts.”
Dr Ben Cross Senior Director (Technology), PhoreMost, commented: “I am excited to have been given this opportunity to work with PhoreMost and the SITESEEKER platform, which has huge potential to uncover not only previously undruggable targets, but also druggable pockets within those targets. I am very much looking forward to working with the team to drive this forward.”
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Nov 27 2024 Istanbul, Turkey
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE